Breaking News Instant updates and real-time market news.

BIIB

Biogen

$332.86

4.55 (1.39%)

09:22
02/07/18
02/07
09:22
02/07/18
09:22

Biogen should be bought on any weakness, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond recommends buying Biogen on any weakness following news that Tysabri's Action2 study in acute ischemic stroke failed to demonstrate a clinical benefit. Tysabri had failed once before in this setting, and the analyst notes he saw little reason for optimism on this study. Raymond says remains focused on the strength of Biogen's multiple sclerosis franchise, Spinraza, and the positive signals from Phase 1 studies in aducanumab. He keeps an Overweight rating on Biogen with a $407 price target.

  • 08

    Mar

  • 30

    May

BIIB Biogen
$332.86

4.55 (1.39%)

01/31/18
UBSW
01/31/18
UPGRADE
Target $410
UBSW
Buy
Biogen upgraded to Buy from Neutral at UBS
UBS analyst Carter Gould upgraded Biogen to Buy and raised his price target for the shares to $410 from $318. The stock closed yesterday down $5.89 to $352.59. The market is underappreciating Biogen's pipeline opportunity and the potential for additional assets to be added through acquisitions, Gould tells investors in a research note. He thinks both together could add $45 per share. The analyst sees "reduced debate over the core pillars" of Biogen's valuation or 2018 earnings estimates with the multiple sclerosis business stabilized, clarity on Spinraza growth over 2018, and aducanumab pivotal Alzheimer's data weighted to 2019/2020. As the company's mid-stage pipeline comes into focus, Gould believes the stock's risk/reward skews positively.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
01/31/18
01/31/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Outperform from Perform at Oppenheimer with analyst Anna Andreeva saying with Nike's (NKE) "onset" of innovation and adidas' (ADDYY) ongoing momentum, Foot Locker is poised to stabilize as 2018 unfolds. 2. American Airlines (AAL) and United Continental (UAL) were upgraded to Outperform from Market Perform at Bernstein. 3. Biogen (BIIB) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the market is underappreciating Biogen's pipeline opportunity and the potential for additional assets to be added through acquisitions. 4. Autoliv (ALV) upgraded to Outperform from Neutral at Baird with analyst David Leiker saying the core business appears to be at the inflection of delivering on strong market share gains from airbag recalls. 5. Time Warner (TWX) upgraded to Buy from Neutral at MoffettNathanson. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.

TODAY'S FREE FLY STORIES

VIPS

Vipshop

$11.65

0.425 (3.79%)

15:25
06/18/18
06/18
15:25
06/18/18
15:25
Options
Vipshop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TFX

Teleflex

$280.29

-1.61 (-0.57%)

15:20
06/18/18
06/18
15:20
06/18/18
15:20
Conference/Events
Teleflex management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 21

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

  • 05

    Sep

GME

GameStop

$14.27

0.355 (2.55%)

15:19
06/18/18
06/18
15:19
06/18/18
15:19
Periodicals
GameStop talks with PE firms after seeing takeover interest, Reuters says »

GameStop is holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Jun

OFC

Corporate Office Properties

$27.36

-0.055 (-0.20%)

15:18
06/18/18
06/18
15:18
06/18/18
15:18
Conference/Events
Corporate Office Properties management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
06/18/18
06/18
15:17
06/18/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
06/18/18
06/18
15:16
06/18/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$14.27

0.355 (2.55%)

15:11
06/18/18
06/18
15:11
06/18/18
15:11
Hot Stocks
Breaking Hot Stocks news story on GameStop 

GameStop trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Jun

HDP

Hortonworks

$19.96

0.86 (4.50%)

15:10
06/18/18
06/18
15:10
06/18/18
15:10
Options
Higher call activity in HortonNetworks as shares see relative strength »

Higher call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:10
06/18/18
06/18
15:10
06/18/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

GME

GameStop

$14.29

0.375 (2.69%)

15:08
06/18/18
06/18
15:08
06/18/18
15:08
Hot Stocks
GameStop jumps after Reuters reports on takeover interest »

Shares of GameStop (GME)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Jun

QTNT

Quotient

$8.33

1.2 (16.83%)

15:08
06/18/18
06/18
15:08
06/18/18
15:08
Conference/Events
Quotient management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

GME

GameStop

$14.30

0.385 (2.77%)

15:06
06/18/18
06/18
15:06
06/18/18
15:06
Periodicals
Breaking Periodicals news story on GameStop »

GameStop talks with PE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Jun

GME

GameStop

$14.31

0.395 (2.84%)

15:05
06/18/18
06/18
15:05
06/18/18
15:05
Hot Stocks
Breaking Hot Stocks news story on GameStop »

GameStop trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Jun

SKX

Skechers

$29.23

-0.2 (-0.68%)

15:05
06/18/18
06/18
15:05
06/18/18
15:05
Options
Skechers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CME

CME Group

$169.09

-0.7 (-0.41%)

14:55
06/18/18
06/18
14:55
06/18/18
14:55
Conference/Events
CME Group management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 26

    Jul

BIG

Big Lots

$41.35

0.11 (0.27%)

14:55
06/18/18
06/18
14:55
06/18/18
14:55
Options
Big Lots put volume heavy and directionally bearish »

Bearish flow noted in Big…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJW

SJW Corp.

$66.69

-0.16 (-0.24%)

, CTWS

Connecticut Water

$65.50

0.5 (0.77%)

14:49
06/18/18
06/18
14:49
06/18/18
14:49
Hot Stocks
SJW sees giving shareholders chance to vote on Connecticut Water deal ASAP »

SJW Group (SJW) commented…

SJW

SJW Corp.

$66.69

-0.16 (-0.24%)

CTWS

Connecticut Water

$65.50

0.5 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$98.07

3.2 (3.37%)

14:45
06/18/18
06/18
14:45
06/18/18
14:45
Recommendations
PTC analyst commentary  »

PTC price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

OXY

Occidental Petroleum

$84.23

0.9 (1.08%)

14:45
06/18/18
06/18
14:45
06/18/18
14:45
Options
Occidental Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$43.86

1.33 (3.13%)

14:41
06/18/18
06/18
14:41
06/18/18
14:41
Recommendations
Etsy analyst commentary  »

Etsy price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

BUD

AB InBev

$96.45

-2.05 (-2.08%)

14:37
06/18/18
06/18
14:37
06/18/18
14:37
Hot Stocks
AB InBev, Kiip launch blockchain mobile ad campaign »

Kiip and AB Inbev…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

GSKY

GreenSky

$24.15

-0.12 (-0.49%)

14:36
06/18/18
06/18
14:36
06/18/18
14:36
Initiation
GreenSky initiated  »

GreenSky initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$83.05

-0.805 (-0.96%)

14:34
06/18/18
06/18
14:34
06/18/18
14:34
Hot Stocks
SOLUTIONS 30, DXC sign strategic partnership in Italy »

SOLUTIONS 30 Italia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$9.50

0.01 (0.11%)

14:25
06/18/18
06/18
14:25
06/18/18
14:25
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
06/18/18
06/18
14:25
06/18/18
14:25
General news
More from Bostic: a possible yield curve inversion »

More from Bostic: a…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.